Indaptus cuts co-CEO and CSO salaries to $60K/year; director rescinds resignation

Indaptus Therapeutics, Inc.

Co-CEO Jeffrey A. Meckler and CSO Michael J. Newman salaries reduced to $60,000 per annum effective Jan 15, 2026.
Director Anthony Maddaluna rescinded his prior resignation and will remain on the Board, including Compensation and Nominating committees.
Salary adjustments are for the remainder of the 2026 calendar year and follow prior employment modifications from Dec 2025.
The reductions are part of a cost-saving measure tied to a securities purchase agreement with investor David E. Lazar.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.